I-BET726

• CAT Number: I001151
• CAS Number: 1300031-52-0
• Molecular Formula: C₂₅H₂₃ClN₂O₃
• Molecular Weight: 435.00
• Purity: ≥95%
• Target: Epigenetic Reader Domain; Apoptosis
• Solubility: DMSO: ≥ 46 mg/mL
• Storage: Store at -20C
• IC50: 41 nM (BRD2); 31 nM (BRD3); 22 nM (BRD4) [1]
• IUPAC Name: 4-[(2S,4R)-1-acetyl-4-(4-chloroanilino)-2-methyl-3,4-dihydro-2H-quinolin-6-yl]benzoic acid
• InChI: InChI=1S/C25H23ClN2O3/c1-15-13-23(27-21-10-8-20(26)9-11-21)22-14-19(7-12-24(22)28(15)16(2)29)17-3-5-18(6-4-17)25(30)31/h3-12,14-15,23,27H,13H2,1-2H3,(H,30,31)/t15-,23+/m0/s1
• InChIKey: FAWSUKOIROHXAP-NPMXOYFQSA-N
• SMILES: C[C@H]1C[C@H](C2=C(N1C(=O)C)C=CC(=C2)C3=CC=C(C=C3)C(=O)O)NC4=CC=C(C=C4)Cl

I-BET726（Cat No.:I001151）is a selective inhibitor of the bromodomain and extraterminal (BET) family of proteins, particularly targeting BRD4. By disrupting the interaction between BET proteins and acetylated histones, I-BET726 inhibits the transcription of oncogenes involved in cancer progression and inflammation. This compound has demonstrated potential in preclinical studies, showing efficacy in various cancer models, including hematological malignancies and solid tumors. I-BET726’s mechanism of action makes it a promising candidate for developing targeted therapies aimed at cancers with elevated BET protein expression, contributing to novel treatment strategies in oncology.

Reference

[1]. Wyce A, et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One. 2013 Aug 23;8(8):e72967.